Anti-cancer drug prices may fall up to 70% as govt caps trade margins on 110 medicines
Synopsis
The Centre has moved to cap trade margins on 110 anti-cancer medicines at 30% of MRP — a measure that could slash retail prices by up to 70% and save patients ₹2,500 crore a year. It is the most sweeping expansion of cancer drug pricing control since a 2019 intervention, and covers branded, generic, patented, and imported medicines alike.
Key Takeaways
The government has reportedly decided to cap trade margins at 30% of MRP on all non-scheduled anti-cancer medicines, effective later in October 2026 .
The cap covers approximately 110 medicines , including 35 patented drugs , spanning branded, generic, domestic, and imported products.
Retail prices of affected medicines could fall by up to 70% , according to official estimates.
The measure is projected to generate annual patient savings of around ₹2,500 crore .
The move expands a similar 2019 intervention that covered only select anti-cancer drugs, now bringing all non-scheduled oncology medicines under the ceiling.
The central government has reportedly decided to cap trade margins at 30 per cent of the maximum retail price (MRP) for all non-scheduled anti-cancer medicines, according to official sources. The move, expected to take effect later this month, could reduce the retail price of affected drugs by as much as 70 per cent, directly easing the financial burden on cancer patients across India.
Scope of the Policy Change
The trade-margin cap will apply to approximately 110 anti-cancer medicines, including 35 patented drugs. Crucially, the restriction covers branded and generic drugs alike, as well as both domestically manufactured and imported products — patented or otherwise. Under the new framework, no non-scheduled anti-cancer medicine can carry a trade margin exceeding 30 per cent of MRP, regardless of its origin or brand status.
Estimated Savings for Patients
Official estimates suggest the intervention could generate annual patient savings of roughly ₹2,500 crore. The government has stated that the benefit will be passed on directly through lower retail prices, rather than absorbed elsewhere in the supply chain. For cancer patients — many of whom face prolonged, high-cost treatment regimens — the relief could be substantial. Out-of-pocket healthcare expenditure remains a leading driver of household financial distress in India, and oncology drugs are among the most expensive categories.
Why the Government Acted Now
Officials said the intervention is designed to address wide variations in trade margins across the supply chain for anti-cancer medicines — variations that, critics argue, have long inflated the price patients pay at the chemist counter far beyond the manufacturer's price. The government believes the cap will bring greater pricing discipline without disrupting medicine availability in the market.
This is not the first time New Delhi has stepped in on this issue. A similar intervention was introduced in 2019, when trade margins on a select group of anti-cancer drugs were capped to check excessive pricing. The new decision significantly expands that policy's reach by bringing all non-scheduled anti-cancer medicines under a single margin ceiling.
What It Means for the Pharma Industry
The measure affects the entire distribution chain — from distributors and stockists to retail pharmacies — that has historically operated on variable and, in several cases, opaque markups on oncology drugs. Both domestic pharmaceutical companies and multinational originators selling patented products in India will be subject to the revised ceiling. Industry observers note that while manufacturers' ex-factory prices are not directly controlled by this measure, the downstream margin cap is likely to force a rationalisation of list prices over time.
What Happens Next
The order is expected to be formally notified later in October 2026. Once in effect, chemists and distributors will be required to comply with the 30 per cent MRP cap on all covered anti-cancer medicines. Patient advocacy groups have welcomed the announcement, though some have called for independent monitoring to ensure the price reductions are actually passed on at the retail level.
Point of View
But the critical question is enforcement. India's 2019 trade-margin cap on select cancer drugs yielded uneven results — compliance at the chemist level was patchy, and margin inflation simply shifted to other line items in the supply chain. The real test this time is whether the government pairs the cap with a credible audit mechanism. With 35 patented drugs in scope, multinational pharma companies will also be watching closely: if list prices come under indirect pressure, some originators may reconsider launch strategies for future oncology products in India — a risk the government will need to weigh against the immediate patient benefit.
NationPress
8 Oct 2026
Frequently Asked Questions
Which anti-cancer medicines will see a price reduction under the new government order?
Approximately 110 non-scheduled anti-cancer medicines will be covered, including 35 patented drugs. The cap applies to branded, generic, domestically manufactured, and imported medicines alike, restricting trade margins to 30% of MRP.
By how much could cancer drug prices fall, and when?
Official estimates indicate prices could fall by up to 70% on affected medicines. The measure is expected to come into effect later in October 2026, once formally notified.
How much money could patients save annually under this policy?
The government estimates annual patient savings of around ₹2,500 crore. The savings are expected to be passed on directly through lower retail prices at chemists and pharmacies.
How does this compare to the 2019 trade-margin cap on cancer drugs?
The 2019 intervention capped margins only on a select group of anti-cancer medicines. The new policy significantly expands that scope to cover all non-scheduled anti-cancer drugs, making it the most comprehensive pricing intervention in this category to date.
What is a trade-margin cap and why does it matter for patients?
A trade-margin cap limits the percentage markup that distributors and retailers can add over a medicine's manufacturer price before it reaches the patient. Without such a cap, trade margins on cancer drugs have historically varied widely, pushing retail prices far above what the drug actually costs to produce or import.
